Clinical Research Protocols
CLINICAL RESEARCH PROTOCOLS
FOR BRAIN CANCER IN ADULTS
This list of clinical research protocols relating to brain cancer
is compiled for your convenience.
The following list of clinical trials for brain tumors in adults is restricted to phase
III studies. For more information about these trials, as well as phase I and II trials in
this area, contact PDQ directly.
MDA-DM-92035, NCI-T92-0114C Phase III Randomized
Trial of PCV (PCB/CCNU/VCR) With vs Without DFMO in Patients With Malignant Gliomas Who
Have Received Radiotherapy (summary last modified: 09/96).
Chairperson: Victor Alan Levin. Lead organization: University of Texas M.D. Anderson
Cancer Center. Age range: 16 and over.
E-2394, SWOG-9508 Phase III Randomized Study of 3
Cycles of 3-Day Continuous-Infusion BCNU/CDDP Followed by Radiotherapy vs Concurrent BCNU
and Radiotherapy for Newly Diagnosed Supratentorial Glioblastoma Multiforme (summary last
modified: 02/96).
Chairperson: Stuart A. Grossman. Lead organization: Eastern Cooperative Oncology Group.
Age range: 18 and over.
EORTC-26881 Phase III Comparison of BCNU vs
BCNU/VCR/ Nimodipine in Patients With Recurrent Malignant Gliomas (summary last modified:
08/92).
Chairperson: Marcel Chatel. Lead organization: EORTC Brain Tumor Cooperative Group. Age
range: 16 to 74.
EORTC-26882 Phase III Randomized Study of
Radiotherapy With DBD Radiosensitization Followed by DBD/BCNU vs Radiotherapy Alone for
Anaplastic Astrocytomas (summary last modified: 03/95).
Chairperson: J. Hildebrand. Lead organization: EORTC Brain Tumor Cooperative Group. Age
range: over 16.
EORTC-26951 Phase III Randomized Study of
Radiotherapy with vs without Adjuvant Procarbazine/ Lomustine/Vincristine (PCV) in
Resected, Highly Anaplastic Oligodendroglioma (summary last modified: 11/96).
Chairperson: M. J. van Den Bent. Lead organization: EORTC Brain Tumor Cooperative Group.
Age range: 16 to 69.
BB-C03/IVB/131, NCI-V96-0909 Phase III Randomized,
Double- Blind, Placebo-Controlled Study of Marimastat (a Matrix Metalloproteinase
Inhibitor) in Glioblastoma Multiforme or Gliosarcoma Following Completion of Conventional
First-Line Treatment (summary last modified: 01/97).
Chairperson: Terry Rugg. Lead organization: British Biotech, Inc. Age range: 18 and over.
GTI-0115, NCI-V96-0990 Phase III Prospective,
Open-Label, Parallel- Group, Randomized, Multicenter Trial Comparing the Efficacy of
Surgery, Radiation, and Injection of Murine Cells Producing Herpes Simplex Thymidine
Kinase Vector Followed by Intravenous Ganciclovir Against the Efficacy of Surgery and
Radiation in the Treatment of Newly Diagnosed, Previously Untreated Glioblastoma
Multiforme (summary last modified: 11/96).
Chairperson: Stephen G. Marcus. Lead organization: Novartis/ Genetic Therapy Inc. Age
range: 18 and over.
DTC-92-001, NCI-V97-1338 Phase III Study of
Liposomal Cytarabine (DepoFoam Encapsulated Cytarabine; DTC 101) vs Standard Therapy for
Neoplastic Meningitis in Patients With Leukemia, Lymphoma, or Solid Tumors (summary last
modified: 12/97).
Chairperson: Linda Paradiso. Lead organization: DepoTech Corp. Age range: 3 and over.
NCCTG-937252, SWOG-9503 Phase III Randomized Study
of BCNU Alone vs BCNU/CDDP and of Standard vs Accelerated Radiotherapy for Grade IV
Gliomas (summary last modified: 10/97).
Chairperson: Jan C. Buckner. Lead organization: North Central Cancer Treatment Group. Age
range: 18 and over.
SWOG-9005, E-S9005 Phase III Randomized
Double-Blind Trial of Mifepristone vs Placebo for Unresectable Meningioma (summary last
modified: 04/97).
Chairperson: Steven M. Grunberg. Lead organization: Southwest Oncology Group. Age range:
18 and over.
EORTC-22845, MRC-BR04 Phase III Randomized
Comparison of Early vs No or Late Radiotherapy in Adult Patients With Grade I/II
Supratentorial Astrocytomas and Oligodendrogliomas (summary last modified: 10/94).
Chairperson: A.B.M.F. Karim. Lead organization: EORTC Radiotherapy Cooperative Group. Age
range: 16 to 65.
RTOG-9305 Phase III Randomized Study of
Radiosurgery Followed by Conventional Radiotherapy With BCNU vs Conventional Radiotherapy
With BCNU in Patients With Supratentorial Glioblastoma Multiforme (summary last modified:
05/96).
Chairperson: Luis Souhami. Lead organization: Radiation Therapy Oncology Group. Age range:
18 and over.
RTOG-9402, INT-0149, NCCTG- 927252 Phase III
Randomized Intergroup Study of Intensive PCV (PCB/CCNU/VCR) Followed by Radiotherapy vs
Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendrogliomas (summary last
modified: 08/94).
Chairperson: J. Gregory Cairncross. Lead organization: Radiation Therapy Oncology Group.
Age range: 18 and over.
Legend for abbreviations:
BB = British Biotech, Inc.
DTC = DepoTech Corporation
E = Eastern Cooperative Oncology Group
EORTC = European Organization for Research on Treatment of Cancer
GTI = Genetic Therapy, Inc.
MDA = University of Texas M.D. Anderson Cancer Center
NCCTG = North Central CancerTreatment Group
RTOG = Radiation Therapy Oncology Group
SWOG = Southwest Oncology Group
Back to Cancer Control Journal Volume 5 Number 2